| Unadjusted HR (95% CI) | Adjusted HRc (95% CI) | Adjusted HRd (95% CI) |
---|---|---|---|
Hepatitis C virus co-infection | 2.49 (1.79, 3.48) | 1.97 (1.33, 2.90) | 2.02 (1.36, 2.99) |
Female sex | 1.56 (1.07, 2.28) | 2.16 (1.42, 3.28) | 2.12 (1.39, 3.23) |
Age ≤ 40 years, per 5 year increase b | 0.97 (0.78, 1.21) | 0.84 (0.67, 1.07) | 0.82 (0.65, 1.04) |
Age > 40 years, per 5 year increase b | 1.59 (1.45, 1.74) | 1.51 (1.35, 1.67) | 1.45 (1.31, 1.62) |
African/Caribbean ethnicity | 0.55 (0.32, 0.94) | 0.79 (0.43, 1.44) | 0.72 (0.39, 1.32) |
Baseline eGFR ≤100 mL/min/1.73 m2, per 10 mL/min/1.73 m2 increase b | 0.56 (0.49, 0.65) | 0.60 (0.52, 0.69) | 0.61 (0.52, 0.70) |
Baseline eGFR >100Â mL/min/1.73Â m2, per 10Â mL/min/1.73Â m2 increase b | 0.86 (0.70, 1.06) | 1.02 (0.80, 1.30) | 1.02 (0.80, 1.28) |
CD4+ cell count, per 100 cells/μL increase | 0.92 (0.86, 0.99) | 0.98 (0.91, 1.06) | 0.97 (0.90, 1.05) |
HIV viral load, per log10 copies/mL increase | 1.18 (1.01, 1.38) | 1.20 (1.01, 1.43) | 1.20 (1.01, 1.42) |
Year of cART initiation, per calendar year increase | 0.99 (0.94, 1.05) | 1.07 (0.99, 1.15) | 1.07 (0.99, 1.15) |
Tenofovir use, per cumulative year of use | 1.17 (1.07, 1.29) | 1.11 (0.99, 1.24) | 1.12 (1.00, 1.25) |
Atazanavir use, per cumulative year of use | 1.16 (1.06, 1.28) | 1.09 (0.98, 1.21) | 1.10 (0.99, 1.23) |
Lopinavir use, per cumulative year of use | 1.12 (1.03, 1.22) | 1.12 (1.02, 1.22) | 1.12 (1.02, 1.23) |
Liver fibrosis (APRI ≥1.5) | 1.59 (1.08, 2.34) | 1.50 (0.98, 2.30) | 1.50 (0.98, 2.30) |
Hypertension | 1.69 (0.96, 2.99) | N/A | 1.70 (0.91, 3.17) |
Diabetes | 3.42 (2.29, 5.10) | N/A | 1.47 (0.96, 2.26) |